--- title: "Greenwich LifeSciences (GLSI) news: going concern" url: "https://aibio.space/companies/greenwich-lifesciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "GLSI going concern and Nasdaq notice news: Greenwich LifeSciences, Inc. files NT 10-K, says annual report will be late. Greenwich LifeSciences, Inc." --- GLSI Greenwich LifeSciences, Inc. NASDAQ · United States # Greenwich LifeSciences (GLSI) news GLSI going concern and Nasdaq notice news Distress · 2026-03-31 ## [Greenwich LifeSciences, Inc. files NT 10-K, says annual report will be late](https://aibio.space/news/greenwich-lifesciences-inc-files-nt-10-k-says-annual-report-will-late/) Greenwich LifeSciences said on March 31, 2026 that its annual report for 2025 would be late. Its 2024 annual report already carried an auditor's going concern paragraph, with $4,091,990 in cash at year end against a $15,788,809 net loss. ## Latest Greenwich LifeSciences news 1. 2025-05-15 Distress [Greenwich LifeSciences delays first-quarter report, expects to file by May 20, 2025](https://aibio.space/news/greenwich-lifesciences-delays-first-quarter-report-expects-file-may-20/) The company filed a late-filing notice for its quarterly report for the three months ended March 31, 2025. Its lead candidate, GLSI-100, is in a Phase III trial that is still expanding. 2. 2025-03-31 Distress [Greenwich LifeSciences files NT 10-K, expects late annual report by April 15, 2025](https://aibio.space/news/greenwich-lifesciences-files-nt-10-k-expects-late-annual-report-april/) The company says it cannot file its 2024 annual report on time and expects to use the 15-day extension. Research and development expenses rose to $12,952,029, and the Phase IIb data behind its lead trial carry unresolved record gaps. ## Greenwich LifeSciences at a glance - **Ticker**: GLSI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $8.9 million ### Related companies - [ALX Oncology Holdings](https://aibio.space/companies/alx-oncology/) NASDAQ: ALXO - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) AMEX: MAIA - [Syndax Pharmaceuticals](https://aibio.space/companies/syndax-pharmaceuticals/) NASDAQ: SNDX - [CorMedix](https://aibio.space/companies/cormedix/) NASDAQ: CRMD - [Longeveron](https://aibio.space/companies/longeveron/) NASDAQ: LGVN - [SKYTECH ORION GLOBAL CORP.](https://aibio.space/companies/skytech-orion-global/) OTC: SKTG - [Trevi Therapeutics](https://aibio.space/companies/trevi-therapeutics/) NASDAQ: TRVI - [Halozyme Therapeutics](https://aibio.space/companies/halozyme-therapeutics/) NASDAQ: HALO ### Also on NASDAQ - [Universe Pharmaceuticals](https://aibio.space/companies/universe-pharmaceuticals/) UPC - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) ACRS - [X4 Pharmaceuticals](https://aibio.space/companies/x4-pharmaceuticals/) XFOR - [Allarity Therapeutics](https://aibio.space/companies/allarity-therapeutics/) ALLR - [Cabaletta Bio](https://aibio.space/companies/cabaletta-bio/) CABA - [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) ASMB ## Greenwich LifeSciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$17.2 million](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/) | [$15.5 million](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/) | | Net income (loss) | [-$19.4 million](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/) | [-$17.4 million](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/) | | Cash from operations | [-$9.9 million](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/) | [-$7.3 million](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/) | | Cash and equivalents | [$6.2 million](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/) | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $8.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Greenwich LifeSciences Has Greenwich LifeSciences issued a going-concern warning? Our latest story on this, dated Mar 31, 2026: "Greenwich LifeSciences, Inc. files NT 10-K, says annual report will be late". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/greenwich-lifesciences-inc-files-nt-10-k-says-annual-report-will-late/). Has Greenwich LifeSciences received a Nasdaq deficiency notice? Our latest story on this, dated May 15, 2025: "Greenwich LifeSciences delays first-quarter report, expects to file by May 20, 2025". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/greenwich-lifesciences-delays-first-quarter-report-expects-file-may-20/). What is the ticker symbol of Greenwich LifeSciences? Greenwich LifeSciences, Inc. trades under the ticker GLSI on NASDAQ. Where is Greenwich LifeSciences listed? Greenwich LifeSciences, Inc. is listed on NASDAQ. What is the SEC CIK of Greenwich LifeSciences? The SEC Central Index Key (CIK) for Greenwich LifeSciences, Inc. is 1799788. Its filings are on SEC EDGAR. How many shares does Greenwich LifeSciences have outstanding? 14,678,208 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Greenwich LifeSciences listed under? Our directory records Greenwich LifeSciences, Inc. under United States. What does Greenwich LifeSciences do? Our directory classifies Greenwich LifeSciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Greenwich LifeSciences? The ISIN recorded for Greenwich LifeSciences, Inc. is US3968791083. Does aibio.space cover Greenwich LifeSciences? aibio.space lists Greenwich LifeSciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Greenwich LifeSciences incorporated? SEC records list its state or country of incorporation as DE. Is Greenwich LifeSciences profitable? Greenwich LifeSciences, Inc. reported a net loss of $19.4 million for the fiscal year ended Dec 31, 2025, and used $9.9 million of cash in operations, per its annual report to the SEC. How much does Greenwich LifeSciences spend on research and development? $17.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Greenwich LifeSciences have? $8.9 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Greenwich LifeSciences (GLSI) stock news? Our latest story on Greenwich LifeSciences, dated Mar 31, 2026: "Greenwich LifeSciences, Inc. files NT 10-K, says annual report will be late". Greenwich LifeSciences said on March 31, 2026 that its annual report for 2025 would be late. Its 2024 annual report already carried an auditor's going concern paragraph, with $4,091,990 in cash at year end against a $15,788,809 net loss. [Source](https://aibio.space/news/greenwich-lifesciences-inc-files-nt-10-k-says-annual-report-will-late/). ## Investor discussion: Greenwich LifeSciences Members talk about Greenwich LifeSciences (GLSI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Greenwich LifeSciences, newest first. Each line links the filing it comes from. 1. 2026-06-01 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/form10-k.htm) 2. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1799788/000149315226014218/formnt10-k.htm) 3. 2025-07-24 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1799788/000164117225020843/form8-k.htm) 4. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1799788/000164117225010936/formnt10-q.htm) 5. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1799788/000164117225001738/formnt10-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GLSI on TradingView](https://www.tradingview.com/symbols/NASDAQ-GLSI/). ## SEC filings and registration - **SEC name**: Greenwich LifeSciences, Inc. - **CIK**: 1799788 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: GLSI (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477 - **Phone**: 203-434-3290 - **Shares outstanding**: 14,678,208 as of 2026-07-24 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1799788/000149315226037147/form10-q.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1799788/000149315226027150/form10-q.htm) filed 2026-06-04 - [10-K](https://www.sec.gov/Archives/edgar/data/1799788/000149315226026651/form10-k.htm) filed 2026-06-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1799788/000149315225028361/form8-k.htm) filed 2025-12-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1799788/000149315225023539/form10-q.htm) filed 2025-11-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1799788/000149315225020623/formdef14a.htm) filed 2025-11-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1799788/000164117225024066/form10-q.htm) filed 2025-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1799788/000164117225020843/form8-k.htm) filed 2025-07-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001799788), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Greenwich LifeSciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GLSI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Greenwich LifeSciences, Inc. - **Ticker**: GLSI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US3968791083 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GLSI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/greenwich-lifesciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Greenwich LifeSciences (GLSI) news: going concern", 2026-10-31, https://aibio.space/companies/greenwich-lifesciences/